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dRelation of Cytochrome P450 2C19 Loss-of-Function Polymorphism
to Occurrence of Drug-Eluting Coronary Stent Thrombosis
Betti Giusti, PhDa,b,*, Anna Maria Gori, BSa,b,d, Rossella Marcucci, MDa,b, Claudia Saracini, PhDa,
Ilaria Sestini, PhDa, Rita Paniccia, BSa,b, Piergiovanni Buonamici, MDb,c, David Antoniucci, MDb,c,
Rosanna Abbate, MDa,b, and Gian Franco Gensini, MDa,b,d
Residual platelet reactivity (RPR) to adenosine 5= diphosphate (ADP) was an independent
predictor of stent thrombosis (ST) in patients receiving drug-eluting stents on dual-
antiplatelet treatment and was associated with the cytochrome P450 (CYP)2C19*2 poly-
morphism. The aim was to evaluate the role of the CYP2C19*2 polymorphism in the
occurrence of ST or the composite end point of ST and cardiac mortality within a 6-month
follow-up in patients undergoing percutaneous coronary interventions with drug-eluting
stent implantation on dual-antiplatelet treatment enrolled in the RECLOSE trial. Seven
hundred seventy-two patients were studied for the CYP2C19*2 polymorphism and RPR
(using 10-M ADP-induced platelet aggregation). Patients with ST or the composite of ST
and cardiac mortality showed a higher prevalence of carriers of the rare allele (54.1% vs
31.3%; p  0.025 and 51.7% vs 31.2%; p  0.020, respectively). At multivariate logistic
regression analysis with ST or ST and cardiac mortality as dependent variables and the
CYP2C19*2 polymorphism, ADP RPR, and additional previously shown clinical and
procedural risk factors for ST as independent variables, the CYP2C19*2 allele (ST odds
ratio [OR] 3.43, 95% confidence interval [CI] 1.01 to 12.78, p  0.047; ST and cardiac
mortality OR 2.70, 95% CI 1.00 to 8.42, p  0.049) and ADP RPR (ST OR 3.08, 95% CI
1.23 to 7.72, p 0.016; ST and cardiac mortality OR 2.90, 95% CI 1.08 to 12.98, p 0.019)
were independent risk factors. Subjects with the contemporary presence of the CYP2C19*2
allele and ADP RPR showed a strong risk of ST or ST and cardiac mortality (OR 5.79, 95%
CI 1.04 to 39.01, p  0.033 and OR 11.45, 95% CI 1.84 to 71.27, p  0.009, respectively).
In conclusion, the CYP2C19*2 allele was associated with the occurrence of ST or ST and
cardiac mortality in high-risk vascular patients on dual-antiplatelet treatment. These findings
could impact on the future design of pharmacogenetic antiaggregant strategies. © 2009
Elsevier Inc. All rights reserved. (Am J Cardiol 2009;103:806–811)
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cSeveral studies investigated the clinical implications of
ntiplatelet drug resistance in patients with coronary artery
isease or stent thrombosis (ST).1–8 Recently, it was shown
hat nonresponsiveness to clopidogrel therapy was an inde-
endent predictor of ST in patients receiving drug-eluting
tents.9,10 Genetic polymorphisms could have a pivotal role
n determining individual susceptibility to antiplatelet drug
esponse. Several polymorphisms in genes coding platelet
omponents (glycoprotein Ia, glycoprotein IIIa, glycopro-
ein Ib-, glycoprotein VI, adenosine 5= diphosphate [ADP]
eceptor P2Y12 [P2Y12], P-selectin, cyclooxygenase-1, and
yclooxygenase-2) or cytochrome P450 (CYP) enzyme iso-
orms (CYP-3A4 and CYP-3A5) have been proposed and
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oi:10.1016/j.amjcard.2008.11.048nvestigated.11–13 Regarding nonresponsiveness to clopi-
ogrel therapy, the active metabolite of this molecule,
hich irreversibly blocked the platelet ADP P2Y12 recep-
or, arose from biochemical reactions14–16 involving several
YP isoforms.11,15 Variability in the catalytic activity of
hese isoforms affected the pharmacodynamic action of clo-
idogrel. Studies of healthy subjects17–20 showed that the
YP2C19*2 allelic variant (681A allele) encoding a defi-
ient drug-metabolizing enzyme21 was associated with im-
aired platelet inhibition to clopidogrel treatment.
Recently, in 1,419 patients with acute coronary syn-
romes undergoing percutaneous coronary interventions on
ual-antiplatelet treatment, we showed that carriers of the
YP2C19*2 allele had significantly higher platelet aggre-
ation after ADP and arachidonic acid stimuli, and the
olymorphism was an independent predictor of antiplatelet
reatment variability.22 These data were confirmed in an
dditional study of 603 patients with non–ST-elevation
cute coronary syndrome.23 In the frame of the Low Re-
ponsiveness to Clopidogrel and Sirolimus- or Paclitaxel-
luting Stent Thrombosis (RECLOSE) trial,9,24 we evalu-
ted the role of the CYP2C19*2 polymorphism on the
ccurrence of drug-eluting ST (primary end point) and the
omposite feature of cardiac mortality and drug-eluting ST
secondary end point) in a 6-month follow-up of 772 pa-
www.AJConline.org
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807Coronary Artery Disease/CYP2C19*2 Polymorphism and Stent Thrombosisients undergoing percutaneous coronary intervention on
ual-antiplatelet treatment.
ethods
The study population included 804 consecutive patients
nrolled in the RECLOSE trial admitted to the Department
f Cardiology of the Careggi Hospital, Florence, Italy, who
nderwent successful sirolimus- or paclitaxel-eluting stent
mplantation and for whom platelet reactivity after dual-
ntiplatelet (clopidogrel and aspirin) treatment was prospec-
ively assessed in previous studies9,24 and partially (n 
10) included in an additional report.22 All patients gave
nformed consent for the clinical study, and 772 of 804
atients gave informed consent for the genetic study. The
tudy was approved by the local ethical review board. Pa-
ients with acute coronary syndromes and ST-segment ele-
ation acute myocardial infarction were included, as well as
atients with left main disease, chronic total occlusions,
ifurcation lesions, or diffuse disease. Exclusion criteria
ere (1) in-hospital death not caused by ST, (2) anticipated
oncompliance with dual-antiplatelet treatment for 6
onths, and (3) premature discontinuation of clopidogrel
herapy. Exclusion criteria included a history of bleeding
iathesis, platelet count 100,000/L, hematocrit 30%,
nd serum creatinine 4.0 mg/dl. All interventions were
erformed according to current standard guidelines, and
ype of stent implanted and use of glycoprotein IIb/IIIa
nhibitors were at the discretion of the operator. All patients
eceived aspirin (325 mg) and a loading dose of clopidogrel
00 mg before the procedure, followed by a maintenance
ose of clopidogrel 75 mg and aspirin 325 mg/day. Unfrac-
ionated heparin 70 IU/kg was used during the procedure as
nticoagulant. In-hospital compliance with clopidogrel and
spirin therapy was verified by nursing staff, and compli-
nce during follow-up was ensured through a structured
nterview. Patients were considered to have hypertension if
ypertension had been diagnosed according to the European
ociety of Hypertension/European Society of Cardiology
uidelines or they were using antihypertensive drugs. Dys-
ipidemia was defined according to the Third Report of the
ational Cholesterol Education Program, and diabetes, ac-
ording to the American Diabetes Association.
Venous blood samples were obtained 12 to 18 hours from
lopidogrel loading in tubes containing 3.2% trisodium citrate.
or patients receiving both the loading dose of clopidogrel and
he glycoprotein IIb/IIIa inhibitor in the catheterization labo-
atory, blood samples were obtained after 6 days.
Platelet aggregation was assessed using platelet-rich plasma
ith the turbidimetric method in a 4-channel aggregometer
APACT4; Helena Laboratories, Milan, Italy) according to our
revious reports.9,22,24 For antiplatelet response, the definition
sed was residual platelet reactivity (RPR) evaluated using 10
M of ADP-induced platelet aggregation (ADP-RPR) 
DP-induced platelet aggregation 70%.9,25
Genomic DNA from 772 patients was isolated from whole
lood using the FlexiGene DNA kit (Qiagen, Hilden, Ger-
any).
The CYP2C19 gene sequence was obtained from Gene-
ank (accession no. NM_000769). The presence of the
YP2C19*2 (rs4244285) polymorphism was determined tsing polymerase chain reaction restriction fragment length
olymorphism analysis.22 The polymerase chain reaction
rimers used were forward 5=-CAGAGCTTGGCATATT-
TATC-3= and reverse 5=-GTAAACACAAAACTAGT-
AATG-3=. Polymerase chain reaction products (321 base
airs) were subjected to digestion with the SmaI restriction
nzyme (Promega Italia, Milan, Italy).
Briefly, the primary end point of the study was definite or
robable ST during a 6-month follow-up. Definite ST was
efined as acute coronary syndrome and either angiographic
r pathologic confirmation of thrombosis. Probable ST was
efined as unexplained death or myocardial infarction in the
erritory supplied by a stented vessel without angiographic
onfirmation. The secondary end point was the composite of
ardiac mortality and definite or probable ST. All events
ere adjudicated by 3 observers who were blinded to lab-
ratory results and not involved in the follow-up process.
ollow-up details were reported in our previous article.9
Statistical analysis was performed using the SPSS statis-
able 1
emographic and clinical characteristics of the 772 enrolled patients
ariable Patients
(n  772)
en 576 (74.6%)
mokers 266 (34.4%)
ypertension 505 (65.4%)
iabetes mellitus 171 (22.2%)
yslipidemia 461 (59.7%)
revious myocardial infarction 191 (24.7%)
revious percutaneous coronary intervention 161 (20.9%)
revious coronary bypass 58 (7.5%)
table angina pectoris 262 (33.9%)
nstable angina pectoris 310 (40.2%)
cute myocardial infarction 197 (25.5%)
ultivessel coronary disease 439 (56.8%)
eft ventricle ejection fraction (%) 47 12
ong-term total occlusion 90 (11.6%)
ifurcation lesion 349 (45.2%)
otal stent length (mm) 37 28
rugs
 Blockers 467 (60.5%)
Calcium antagonists 127 (16.4%)
Statins 690 (89.4%)
Angiotensin-converting enzyme inhibitors 636 (82.4%)
Glycoprotein IIb/IIIa inhibitors 334 (43.3%)
roton pump inhibitors 732 (94.8%)
able 2
linical outcomes
linical Outcome Overall
(n  772)
CYP2C19 Polymorphism p
Value
*1*1
(n  525)
*1*2  *2*2
(n  247)
efinite/probable ST 24 (3.1%) 11 (2.1%) 13 (5.3%) 0.025
Definite 11 (1.4%) 5 (1.0%) 6 (2.5%) 0.100
Probable 13 (1.7%) 6 (1.1%) 7 (2.8%) 0.083
ardiac mortality 18 (2.3%) 8 (1.5%) 10 (4.0%) 0.037
omposite of cardiac
mortality and ST
29 (3.8%) 14 (1.8%) 15 (6.1%) 0.020ical package, version 11.5 (SPSS Inc., Chicago, Illinois).
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808 The American Journal of Cardiology (www.AJConline.org)e tested that the allele frequencies conformed to Hardy-
einberg equilibrium proportions using chi-square test.
enotype and allele frequencies were compared between
roups using chi-square analysis. Categorical variables
ere expressed as frequencies and percentages. Unless oth-
rwise indicated, data were given as median and range.
omparisons of continuous variables between patients with
nd without ST or the composite of ST and cardiac mortality
ere performed using nonparametric Mann-Whitney U test.
Univariate and multivariate logistic regression analysis
as used to estimate odds ratios (ORs) and 95% confidence
ntervals (CIs) for the development of ST or occurrence of
he secondary end point. Multivariate logistic regression
nalysis was performed with ST or the composite of ST and
ardiac mortality as the dependent variable and the
YP2C19*2 allele, ADP-RPR, traditional cardiovascular
isk factors, and additional previously shown9 clinical and
rocedural risk factors for ST (total chronic occlusion, mul-
ivessel disease, bifurcation lesion, acute myocardial infarc-
ion, previous myocardial infarction, total stent length, and
eft ventricular ejection fraction) as independent variables.
p value 0.05 was chosen as the cutoff for statistical
70
0
p=0.02568.7%
n=514
*1/*1 
n=234
31.3%
n=11 n=13
45.8%
54.1%
(%) 40
30
20
10
50
60
*1/*2
+*2/*2
80
*1/*1 
CYP2C19
genotype *1/*2
+*2/*2
p=0.02068.8%
n=511
*1/*1 
n=232
31.2%
n=14 n=15
48.3%
51.7%
*1/*2
+*2/*2
*1/*1 *1/*2
+*2/*2
=  748  without                    
stent thrombosis
=   24  with                   
stent thrombosis
=  743  without cardiac mortality 
and stent thrombosis
=  29  with cardiac mortality and 
igure 1. Prevalence of homozygote wild-type and rare allele carriers
heterozygotes and homozygotes) for the CYP2C19*2 polymorphism in
atients with or without the occurrence of 6-month follow-up drug-eluting
T and the composite end point of ST and cardiac mortality.
able 3
revalence of CYP2C19 genotypes, ADP-RPR, and contemporary presen
nd point of stent thrombosis (ST) and the secondary end point of compo
ariables No ST
(n  748)
ST
(n  24)
p Valu
YP2C19 polymorphism
2/2 24 (3.2%) 2 (8.3%)
1/2 210 (28.1%) 11 (45.8%) 0.046
1/1 514 (68.7%) 11 (45.8%)
DP RPR
Yes 102 (13.6%) 8 (33.3%) 0.001
No 646 (86.4%) 16 (66.7%)
DP RPR  CYP2C19*2
Yes 34 (4.5%) 6 (25.0%) 0.000
No 714 (95.5%) 18 (75.0%)ignificance. pesults
Demographic and clinical characteristics of patients are
isted in Table 1.
The genotype distribution of the CYP2C19*2 polymor-
hism in the overall patient population was 3.4% homozy-
otes *2/*2, 28.6% heterozygotes *1/*2, and 68.0% ho-
ozygotes *1/*1. The rare allele frequency in the overall
igure 2. Kaplan-Meier analysis of the primary end point for the presence
f the CYP2C19*2 polymorphism.
igure 3. Kaplan-Meier analysis of the primary end point for the contem-
orary presence of the CYP2C19*2 polymorphism and ADP-RPR.
DP-RPR plus the CYP2C19*2 polymorphism according to the primary
and cardiac mortality
No ST  Cardiac Mortality
(n  743)
ST  Cardiac Mortality
(n  29)
p Value
24 (3.2%) 2 (6.9%)
208 (28.0%) 13 (44.8%) 0.061
511 (68.8%) 14 (48.3%)
100 (13.5%) 10 (34.5%) 0.001
643 (86.5%) 19 (65.5%)
33 (4.4%) 7 (24.1%) 0.0001
710 (95.6%) 22 (75.9%)ce of A
site ST
e
1atient population of the CYP2C19*2 polymorphism was
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809Coronary Artery Disease/CYP2C19*2 Polymorphism and Stent Thrombosis.177. The CYP2C19*2 polymorphism was in Hardy-Wein-
erg equilibrium.
No statistically significant difference was observed be-
ween carriers of the CYP2C19*2 rare allele (heterozygotes
lus homozygotes) and wild-type homozygotes for all the
onsidered demographic (age and gender), clinical (smok-
ng habit, hypertension, diabetes, dyslipidemia, previous
yocardial infarction, previous percutaneous coronary in-
ervention, previous coronary artery bypass grafting, stable
ngina, unstable angina, acute myocardial infarction, mul-
ivessel disease, left ventricular ejection fraction, chronic
otal occlusion, bifurcation lesion, and total stent length),
nd therapeutic ( blockers, calcium antagonists, statins,
ngiotensin-converting enzyme inhibitors, glycoprotein IIb/
IIa inhibitors, and proton pump inhibitors) variables (data
ot shown).
Table 2 lists clinical outcomes at 6 months. The ST rate
t 6 months was 3.1%. There were no differences in ST
ates among patients receiving sirolimus- or paclitaxel-elut-
ng stents or both type of stents (3.4%, 2.3%, and 5.5%,
espectively). Most ST (64%) was subacute and occurred at
mean of 54  62 days (range, 4 to 180) from stent
mplantation, whereas no patient had acute ST. The inci-
ence of the composite end point of cardiac death and ST
as 3.8%. The incidence of the primary and composite end
oints significantly differed between wild-type homozygous
atients (*1/*1) and carriers of the CYP2C19*2 rare allele
*1/*2 plus *2/*2 genotypes; Table 2). Concerning analysis
ith definite and probable ST separately, similar results
ere observed even if the full statistical significance was
ot reached (Table 2).
Genotype distribution of the CYP2C19*2 polymorphism
as significantly different between patients with or without
T and showed a trend to statistical significance between
atients with or without the secondary end point (ST and
ardiac mortality; Table 3). The prevalence of carriers of the
are allele was significantly higher in patients with (54.1%)
han without ST (31.3%) and in patients with ST and cardiac
ortality (51.7%) than in patients without ST and cardiac
ortality (31.2%; p  0.025 and p  0.020, respectively;
igure 1).
Patients with ST had significantly higher (p  0.048)
latelet aggregation using ADP (56%, range 14% to 100%)
han patients without the occurrence of ST (46%, range 1%
able 4
he CYP2C19*2 allele and ADP-RPR odds ratios for the occurrence of s
ith acute coronary syndrome undergoing percutaneous coronary interven
Univariate Analysis
T
CYP2C19*2 allele 2.59 (1.15–5.88)
ADP RPR 3.17 (1.32–7.59)
T and cardiac mortality
CYP2C19*2 allele 2.36 (1.12–4.97)
ADP RPR 3.38 (1.53–7.49)
* Multivariate logistic regression analysis was performed with ST or
YP2C19*2 allele, ADP-RPR, traditional cardiovascular risk factors, and
hronic occlusion, multivessel disease, bifurcation lesion, acute myocardia
jection fraction) as independent variables.o 100%). cCarriers of the rare allele of the CYP2C19 polymorphism
ad significantly higher (p  0.001) ADP-induced platelet
ggregation than noncarriers of the rare allele (51%, range
% to 100% vs 45%, range 1% to 100%, respectively).
In patients with ST, ADP-RPR was more prevalent
33.3%) with respect to patients without ST (13.6%; p 
.001; Table 3). Moreover, in patients with ST, a statisti-
ally significant (p 0.0001) higher prevalence of subjects
ith the contemporary presence of ADP-RPR plus the
YP2C19*2 polymorphism (25%) with respect to patients
ithout ST (4.5%) was observed (Table 3).
Similar results were observed concerning the secondary
nd point of composite cardiac mortality and ST (Table 3).
Event-free survival curves of ST (primary end point) ac-
ording to the presence of the rare allele of the CYP2C19*2
olymorphism and the contemporary presence of ADP-RPR
lus CYP2C19*2 are shown in Figures 2 and 3, respectively.
Univariate and multivariate logistic regression analyses
or the occurrence of ST and the composite end point of ST
nd cardiac mortality were listed in Table 4. At multivariate
ogistic regression analysis adjusted for the presence of
DP-RPR, traditional cardiovascular risk factors, and ad-
itional previously shown9 clinical and procedural risk fac-
ors for ST, the CYP2C19*2 gene polymorphism resulted
n independent risk factor for ST and the composite end
oint of cardiac mortality and ST (Table 4). Moreover, in
his analysis, ADP-RPR was associated with a higher risk of
T and the composite end point of cardiac mortality and ST
ndependently of the CYP2C19*2 polymorphism (Table 4).
At multivariate logistic regression analysis adjusted for
raditional cardiovascular risk factors and clinical and pro-
edural risk factors for ST, the contemporary presence of
DP-RPR plus the CYP2C19*2 polymorphism was a
trong independent risk factor for ST (OR 5.79, 95% CI
.04 to 39.01, p  0.033). Similar results at multivariate
egression analysis were obtained concerning the composite
nd point of cardiac mortality and ST (OR 11.45, 95% CI
.84 to 71.27, p  0.009).
iscussion
In this study, we investigated the role of the CYP2C19*2
oss-of-function polymorphism in determining the risk of oc-
urrence of drug-eluting ST and the composite end point of
ombosis (ST) or the composite of ST and cardiac mortality in patients
Value Multivariate Analysis* p Value
0.022 3.43 (1.01–12.78) 0.047
0.010 3.08 (1.23–7.72) 0.016
0.024 2.70 (1.00–8.42) 0.049
0.003 2.90 (1.08–12.98) 0.019
posite of ST and cardiac mortality as the dependent variable and the
onal previously shown9 clinical and procedural risk factors for ST (total
tion, previous myocardial infarction, total stent length, and left ventricletent thr
tion
p
the com
additi
l infarcardiac mortality and ST in patients treated with combined
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810 The American Journal of Cardiology (www.AJConline.org)lopidogrel and aspirin therapy enrolled in the RECLOSE trial.
he present study provided the novel finding that the 2C19*2
llele of the CYP2C19 gene was an independent risk factor for
rug-eluting ST. Moreover, RPR to ADP in the acute peripro-
edural phase was associated with a higher risk of ST inde-
endently of the CYP2C19*2 polymorphism, thus underlying
he predictive role of both acute platelet hyperreactivity and the
YP2C19*2 genetic determinant.
Recently, the CYP2C19*2 allelic variant, encoding a defi-
ient drug-metabolizing enzyme CYP2C19, was associated
ith impaired platelet inhibition after acute and long-term oral
lopidogrel administration in healthy subjects.17–20 The asso-
iation between the CYP2C19*2 polymorphism and platelet
eactivity has been shown in patients with acute coronary
yndromes in our recent report of 1,419 patients,22 an addi-
ional study of 603 patients with non–ST elevation acute cor-
nary syndromes,23 and this study.
Our data showed that the CYP2C19*2 polymorphism
as an independent risk factor for ST and also the compos-
te end point of cardiac mortality and ST when the presence
f the CYP2C19*2 polymorphism was evaluated in multi-
ariate logistic regression analysis adjusted for ADP-RPR,
raditional cardiovascular risk factors, and additional possi-
le clinical and procedural risk factors for ST (total long-
erm occlusion, multivessel disease, bifurcation lesion,
cute myocardial infarction, previous myocardial infarction,
otal stent length, and left ventricle ejection fraction). Inter-
stingly, the present findings indicated that the contempo-
ary presence of ADP-RPR and the CYP2C19*2 polymor-
hism was the strongest predictor of ST complication or the
omposite of ST and cardiac mortality with respect to the
YP2C19*2 polymorphism and ADP-RPR per se.
Our data provided the 2 insights that (1) mining of the
YP2C19*2 polymorphism as a risk factor for ST was only
artially linked to its role in determining the ADP-RPR
henotype observed in the acute periprocedural phase, and
2) other genetic and acquired determinants of RPR in
ddition to the CYP2C19*2 polymorphism might have a
ole in determining the 6-month clinical outcome in these
igh-risk vascular patients. Recently, a CYP2C9 polymor-
hism in a different isoform of CYP was associated with
iminished pharmacodynamic response and poor responder
tatus to clopidogrel therapy in healthy subjects.18 More-
ver, other polymorphisms, such as glycoprotein Ia C807T,
lycoprotein IIIa Leu33Pro, cyclooxygenase-1, and cyclo-
xygenase-2, might contribute to the increased thrombotic
isk in these patients.11–13 Moreover, omeprazole was
hown to significantly decrease the effect of clopidogrel on
latelet activation.26 Dual-antiplatelet therapy was fre-
uently associated with proton pump inhibitors to prevent
astrointestinal bleeding, and the isoenzyme CYP2C19 was
lso involved in the metabolism of proton pump inhibi-
ors.27 However, in our study, there was no difference be-
ween patients with or without ST in the prevalence of
roton pump inhibitor treatment.
By considering the contemporary presence of ADP-RPR
lus the CYP2C19*2 polymorphism, we might identify
bout 95% of subjects who did not develop ST with spec-
ficity of 0.95 and sensitivity of 0.25. Consequently, a strong
ffort should be made to identify new genetic and nonge-
etic risk factors for ST and, most importantly, evaluate thempact of the contemporary presence of different functional
olymorphisms of CYP2C19 and other genes involved in
ntiplatelet therapy responsiveness, as well as other RPR
eterminants to develop a combined score for better predic-
ion of ST and cardiac mortality.
Recently, Trenk et al28 confirmed an association between
he CYP2C19*2 polymorphism and platelet function phe-
otype, as well as an association of high platelet reactivity
n clopidogrel therapy with poor clinical outcome, which
e had already reported in 2 previous studies,9,13 but they
id not show a significant association between the
YP2C19*2 polymorphism and clinical outcomes. It was
onceivable that the higher number of thrombotic events
elated to the higher risk profile of our patients and the
ifferent choice of clinical outcomes allowed us to detect a
ignificant association between the CYP2C19*2 polymor-
hism and ischemic events, namely ST and cardiac death.
The different timing of venous blood sampling in glyco-
rotein IIb/IIIa inhibitor–treated patients might be a limita-
ion of the study. Nevertheless, if present, the residual effect
f glycoprotein IIb/IIIa inhibitors on platelet aggregation
as modest and would result in mild underestimation of the
umber of patients with RPR. In addition, data from pub-
ished reports showed that platelet aggregation induced us-
ng ADP fully recovered 5 days after discontinuation of
bciximab therapy.29
By increasing the clopidogrel maintenance dose (75
g) or using other drugs (i.e., prasugrel) that are not influ-
nced by the polymorphism, it could be possible to increase
he entity of platelet inhibition or override, at least in part,
he nonresponsiveness to the standard maintenance dose.
ur findings emphasized the need for additional studies
imed to clarify whether a more intense therapy designed
or correction of inadequate suppression of platelet reactiv-
ty could improve outcome in this clinical setting without
ncreasing the major bleeding complications.
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